American Diabetes Association

Skip to Main Content

Table 2—

The effect of baseline strata on the relative risk of developing type 2 diabetes over 4 years in patients, irrespective of treatment

Variable	Hazard ratio	95% CI	P
Treatment group: orlistat versus placebo	0.63	(0.46–0.87)	0.0052
Glucose tolerance: impaired versus normal	10.60	(7.30–15.40)	<0.0001
Sex: male versus female	1.41	(1.02–1.96)	0.0390
Age (years): >44^* vs. ≤44	1.44	(1.02–2.04)	0.0383
BMI (kg/m²): ≥37 vs. <37^*	1.36	(0.97–1.91)	0.0726

Variable	Hazard ratio	95% CI	P
Treatment group: orlistat versus placebo	0.63	(0.46–0.87)	0.0052
Glucose tolerance: impaired versus normal	10.60	(7.30–15.40)	<0.0001
Sex: male versus female	1.41	(1.02–1.96)	0.0390
Age (years): >44^* vs. ≤44	1.44	(1.02–2.04)	0.0383
BMI (kg/m²): ≥37 vs. <37^*	1.36	(0.97–1.91)	0.0726

*

Median.